- Home
- CAC vs RVPHW Comparison
CAC vs RVPHW Comparison
Compare CAC & RVPHW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CAC
- RVPHW
- Stock Information
- Founded
- CAC 1875
- RVPHW 2018
- Country
- CAC United States
- RVPHW United States
- Employees
- CAC N/A
- RVPHW 14
- Industry
- CAC Major Banks
- RVPHW Biotechnology: Pharmaceutical Preparations
- Sector
- CAC Finance
- RVPHW Health Care
- Exchange
- CAC Nasdaq
- RVPHW Nasdaq
- Market Cap
- CAC N/A
- RVPHW N/A
- IPO Year
- CAC 1997
- RVPHW N/A
- Fundamental
- Price
- CAC $39.34
- RVPHW $0.07
- Analyst Decision
- CAC Hold
- RVPHW
- Analyst Count
- CAC 3
- RVPHW 0
- Target Price
- CAC $47.33
- RVPHW N/A
- AVG Volume (30 Days)
- CAC 54.8K
- RVPHW 22.4K
- Earning Date
- CAC 05-06-2025
- RVPHW 03-14-2025
- Dividend Yield
- CAC 4.27%
- RVPHW N/A
- EPS Growth
- CAC 2.54
- RVPHW N/A
- EPS
- CAC 3.09
- RVPHW N/A
- Revenue
- CAC $184,324,000.00
- RVPHW N/A
- Revenue This Year
- CAC $40.83
- RVPHW N/A
- Revenue Next Year
- CAC $5.29
- RVPHW N/A
- P/E Ratio
- CAC $12.75
- RVPHW N/A
- Revenue Growth
- CAC 13.26
- RVPHW N/A
- 52 Week Low
- CAC $30.78
- RVPHW $0.13
- 52 Week High
- CAC $50.07
- RVPHW $0.15
- Technical
- Relative Strength Index (RSI)
- CAC 45.56
- RVPHW N/A
- Support Level
- CAC $39.33
- RVPHW N/A
- Resistance Level
- CAC $40.32
- RVPHW N/A
- Average True Range (ATR)
- CAC 0.72
- RVPHW 0.00
- MACD
- CAC -0.15
- RVPHW 0.00
- Stochastic Oscillator
- CAC 24.14
- RVPHW 0.00
About RVPHW Reviva Pharmaceuticals Holdings Inc.
Reviva Pharmaceuticals Holdings Inc is a late-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, inflammatory, and cardiometabolic diseases. The company uses a chemical genomics-driven technology platform and proprietary chemistry to develop new medicines. The company's pipeline currently has two drug candidates, Brilaroxazine (RP5063) which is intended to treat multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease and Parkinson's disease psychosis and its other drug candidate is RP1208.